Successful Outpatient Management of Diffuse Photosensitive Bullous Dermatitis Following Pembrolizumab Therapy.

Journal Article (Journal Article)

Immune checkpoint inhibitors including programmed death protein 1 inhibitors show great therapeutic benefit for numerous advanced malignancies but can cause a spectrum of immune-related adverse events, with cutaneous toxicity being a common presentation. This report includes two cases of lung adenocarcinoma treated with pembrolizumab that developed rare presentations of diffuse bullous lichenoid dermatitis involving >50% total body surface area. These cases were successfully treated in the outpatient setting with oral dexamethasone and minimal interruption of pembrolizumab therapy, a more conservative approach than current guidelines suggest. J Drugs Dermatol. 2022;21(6):668-670. doi:10.36849/JDD.6715.

Full Text

Duke Authors

Cited Authors

  • Penny, C; Nath, N; Kheterpal, M

Published Date

  • June 1, 2022

Published In

Volume / Issue

  • 21 / 6

Start / End Page

  • 668 - 670

PubMed ID

  • 35674751

International Standard Serial Number (ISSN)

  • 1545-9616

Digital Object Identifier (DOI)

  • 10.36849/JDD.6715


  • eng

Conference Location

  • United States